Donna A Wall

List of Publications by Year
in descending order

106 papers	6,968 citations	136885 32 h-index	60583 81 g-index
108 all docs	108 docs citations	108 times ranked	7769 citing authors

#	Article	IF	Citations
1	Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2004, 39, 1407-1416.	2.9	1,248
2	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î²-Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	13.9	939
3	Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease. New England Journal of Medicine, 2005, 352, 2069-2081.	13.9	642
4	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1150-1163.	2.0	506
5	Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study. Journal of Clinical Oncology, 2001, 19, 3463-3469.	0.8	293
6	One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. New England Journal of Medicine, 2014, 371, 1685-1694.	13.9	246
7	Infant Cancer in the U.S.. Journal of Pediatric Hematology/Oncology, 1997, 19, 428-432.	0.3	235
8	Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases. Biology of Blood and Marrow Transplantation, 2006, 12, 184-194.	2.0	178
9	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood, 2015, 125, 3501-3508.	0.6	177
10	Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood, 2008, 111, 3276-3285.	0.6	143
11	Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT). Biology of Blood and Marrow Transplantation, 2005, 11, 149-160.	2.0	137
12	Randomized clinical trial of therapeutic music video intervention for resilience outcomes in adolescents/young adults undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group. Cancer, 2014, 120, 909-917.	2.0	127
13	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Childrenâ€™s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood, 2014, 123, 2017-2025.	0.6	109
14	Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. Blood, 2012, 119, 2949-2955.	0.6	106
15	Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Update of the 2005 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 505-522.	2.0	96
16	Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. Journal of Clinical Immunology, 2000, 20, 466-476.	2.0	82
17	Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 386-397.	2.0	81
18	Prevalence and Clinical Features of Inflammatory Bowel Diseases Associated With Monogenic Variants, Identified by Whole-Exome Sequencing in 1000 Children at a Single Center. Gastroenterology, 2020, 158, 2208-2220.	0.6	81

#	Article	IF	Citations
19	Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood, 2002, 99, 3151-3157.	0.6	77
20	Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young Children: The Cord Blood Transplantation Study (COBLT) Experience. Biology of Blood and Marrow Transplantation, 2005, 11, 637-646.	2.0	76
21	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2005, 11, 823-861.	2.0	67
22	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biology of Blood and Marrow Transplantation, 2015, 21, 67-73.	2.0	62
23	Randomized Trial of Hydroxychloroquine for Newly Diagnosed Chronic Graft-versus-Host Disease in Children: A Childrenâ€™s Oncology Group Study. Biology of Blood and Marrow Transplantation, 2012, 18, 84-91.	2.0	56
24	Bone marrow transplantation for the treatment of Î±-mannosidosis. Journal of Pediatrics, 1998, 133, 282-285.	0.9	50
25	The contribution of nonmalignant tumors to CNS tumor incidence rates among children in the United States. Cancer Causes and Control, 1999, 10, 101-105.	0.8	50
26	Umbilical cord blood transplantation in Wiskott Aldrich syndrome. Journal of Pediatrics, 2003, 142, 519-523.	0.9	49
27	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49
28	Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells. Cytotherapy, 2018, 20, 639-649.	0.3	49
29	Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders. Journal of Allergy and Clinical Immunology, 1999, 103, 823-832.	1.5	46
30	Use of G-CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatric Blood and Cancer, 2006, 46, 414-421.	0.8	46
31	Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants. Biology of Blood and Marrow Transplantation, 2009, 15, 360-366.	2.0	43
32	A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatric Blood and Cancer, 2013, 60, 1868-1874.	0.8	42
33	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent Î²-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. Blood, 2020, 136, 3-4.	0.6	34
34	Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2010, 54, 291-298.	0.8	33
35	Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1205-1214.	2.0	32
36	Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1776-1784.	2.0	30

#	Article	IF	Citations
37	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency. Journal of Clinical Immunology, 2016, 36, 713-724.	2.0	30
38	Interferon Î³ induced compositional changes in human bone marrow derived mesenchymal stem/stromal cells. Clinical Proteomics, 2017, 14, 26.	1.1	30
39	Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. Journal of Pediatrics, 1999, 135, 387-389.	0.9	29
40	A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. JCI Insight, 2018, 3, .	2.3	29
41	Thiotepa and Cyclophosphamide with Stem Cell Rescue for Consolidation Therapy for Children with High-Risk Neuroblastoma. Journal of Pediatric Hematology/Oncology, 1998, 20, 49-54.	0.3	28
42	A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). British Journal of Haematology, 2009, 147, 691-699.	1.2	27
43	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e27034.	0.8	26
44	Phase I study of tandem highâ€dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study. Pediatric Blood and Cancer, 2011, 57, 506-513.	0.8	25
45	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 1714-1721.	2.0	24
46	Aberrant splicing contributes to severe Î±-spectrinâ€“linked congenital hemolytic anemia. Journal of Clinical Investigation, 2019, 129, 2878-2887.	3.9	24
47	Human umbilical cord blood cells can be induced to express markers for neurons and glia. Cell Transplantation, 2002, 11, 261-4.	1.2	24
48	Enhanced human hematopoietic stem and progenitor cell engraftment by blocking donor T cellâ€“mediated TNFÎ± signaling. Science Translational Medicine, 2017, 9, .	5.8	23
49	Publication bias is present in blood and marrow transplantation: an analysis of abstracts at an international meeting. Blood, 2011, 118, 6698-6701.	0.6	20
50	CD56 ^{bright} natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica, 2017, 102, 1936-1946.	1.7	20
51	The Evolution of the Evidence-Based Review: Evaluating the Science Enhances the Art of Medicineâ€”Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 819-822.	2.0	19
52	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. Pediatric Blood and Cancer, 2006, 46, 719-722.	0.8	19
53	Regulatory issues in cord blood banking and transplantation. Best Practice and Research in Clinical Haematology, 2010, 23, 171-177.	0.7	17
54	Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency. Clinical Immunology, 2019, 205, 138-147.	1.4	17

#	Article	IF	Citations
55	Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: A Pediatric Oncology Group study (POG 9376). Pediatric Blood and Cancer, 2009, 52, 346-350.	0.8	16
56	Plerixafor Successfully Rescues Poor Mobilizers Resulting in Adequate CD34 Cell Numbers However Stem Cell Products Yield Lower Numbers of CFU/CD34 and Delayed Neutrophil Engraftment. Blood, 2014, 124, 2450-2450.	0.6	16
57	Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation. Pediatric Blood and Cancer, 2013, 60, 1044-1047.	0.8	14
58	Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies. Cytotherapy, 2022, 24, 2-9.	0.3	14
59	Healthâ€Related Quality of Life in Survivors of Highâ€Risk Neuroblastoma After Stem Cell Transplant: A National Populationâ€Based Perspective. Pediatric Blood and Cancer, 2016, 63, 1615-1621.	0.8	11
60	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. Blood, 2012, 120, 359-359.	0.6	11
61	Abnormalin vitro thymocyte differentiation in a patient with severe combined immunodeficiency-Nezelof's syndrome. Journal of Clinical Immunology, 1996, 16, 151-158.	2.0	10
62	Expression of Human Alpha1Antitrypsin in Murine Hematopoietic Cellsin Vivoafter Retrovirus-Mediated Gene Transfer. Molecular Genetics and Metabolism, 1998, 63, 198-204.	0.5	10
63	Jumping Translocations of 3q in Acute Promyelocytic Leukemia. Cancer Genetics and Cytogenetics, 1999, 108, 149-153.	1.0	10
64	Hematopoietic Stem Cell Transplantation After First Marrow Relapse of Non-T, Non-B Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2006, 28, 210-215.	0.3	10
65	Methodology for Updating Published Evidence-Based Reviews Evaluating the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: A Policy Statement by the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 761-762.	2.0	9
66	Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 569-575.	2.0	9
67	Upper Versus Lower Endoscopy in the Diagnosis of Graft-Versus-Host Disease. Journal of Clinical Gastroenterology, 2017, 51, 701-706.	1.1	9
68	Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 1172-1178.	2.0	7
69	Expression and function of phosphoinositide 3â€kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow. British Journal of Haematology, 2019, 185, 883-887.	1.2	5
70	Effect of different conditioning regimens on survival and engraftment for children with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoeitic stem cell transplantation: A single institution experience. Pediatric Blood and Cancer, 2020, 67, e28477.	0.8	5
71	Delirium in Children Undergoing Hematopoietic Cell Transplantation: A Multi-Institutional Point Prevalence Study. Frontiers in Oncology, 2021, 11, 627726.	1.3	5
72	Sequential paternal haploidentical donor liver and HSCT in EPP allow discontinuation of immunosuppression postâ€organ transplant. Pediatric Transplantation, 2021, 25, e14040.	0.5	4

#	Article	IF	Citations
73	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. Blood, 2012, 120, 470-470.	0.6	4
74	Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study. Blood, 2013, 122, 919-919.	0.6	4
75	A child with reading impairment and a family history of adrenoleukodystrophy. Seminars in Pediatric Neurology, 1999, 6, 233-237.	1.0	3
76	Primary Graft Failure (GF) after Unrelated Donor Cord Blood Transplants (UCBT): Risk Factors and Management.. Blood, 2006, 108, 44-44.	0.6	3
77	Expanding Spectrum of Malignancies in ALPS: A Cancer Predisposing Syndrome?.. Blood, 2012, 120, 2149-2149.	0.6	3
78	Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours. Xenobiotica, 2013, 43, 276-282.	0.5	2
79	Routine filtration of hematopoietic stem cell products: the time has arrived. Transfusion, 2015, 55, 1980-1984.	0.8	2
80	Umbilical cord blood: importance of supporting public banks. American Family Physician, 2011, 84, 638.	0.1	2
81	Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. Biology of Blood and Marrow Transplantation, 2016, 22, S37-S38.	2.0	1
82	Transplantationâ€associated thrombotic microangiopathy isolated to a congenital anomaly of the lung. Pediatric Transplantation, 2017, 21, e12824.	0.5	1
83	Allogeneic hematopoietic stem cell transplantation in an adolescent with Prader-Willi syndrome â€“ unique considerations. Pediatric Hematology and Oncology, 2021, , 1-7.	0.3	1
84	Higher Cell Dose and CD34+ Content Improves Engraftment Following Unrelated Donor Cord Blood Transplantation (CBT): A Report of the National Marrow Donor Program (NMDP) Cord Blood (CB) Experience.. Blood, 2004, 104, 975-975.	0.6	1
85	Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report.. Blood, 2005, 106, 2046-2046.	0.6	1
86	Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).. Blood, 2006, 108, 3232-3232.	0.6	1
87	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. Blood, 2011, 118, 837-837.	0.6	1
88	Proteomic Analysis of Reprograming of Mesenchymal Stem/Stromal Cells (MSC) Following Interferon Gamma Identifies Pathways That Are Upregulated in Suppression. Blood, 2015, 126, 384-384.	0.6	1
89	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. Blood, 2016, 128, 1231-1231.	0.6	1
90	Comparison of Outcomes of Mismatched Related Stem Cell and Unrelated Cord Blood Transplants in Children with Severe T-Cell Deficiencies.. Blood, 2009, 114, 664-664.	0.6	1

#	Article	IF	Citations
91	Peripheral venous catheter collection of immune effector cells and hematopoietic stem cells is feasible and safe in older pediatric patients. Transfusion, 2021, 61, 3413-3419.	0.8	1
92	Effect of Autograft CD34 + Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors. Transplantation and Cellular Therapy, 2022, 28, S252-S253.	0.6	1
93	Impact of CD34+ Cell Dose on Outcome Among Children Undergoing Autologous Hematopoietic Stem Cell Transplant for High-Risk Neuroblastomas. Transplantation and Cellular Therapy, 2022, 28, S251-S252.	0.6	1
94	Umbilical Cord Blood Stem Cell Transplantation in Severe T-Cell Immunodeficiency Disorders. Pediatric Asthma, Allergy and Immunology, 2005, 18, 189-200.	0.2	0
95	Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the Cibmtr. Biology of Blood and Marrow Transplantation, 2014, 20, S64.	2.0	0
96	Access to Hematopoietic Stem Cell Transplantation Among Pediatric Patients with Acute Leukemia: A Population-Based Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, S37-S38.	2.0	0
97	A Novel Secondary Neoplasm Following Allogeneic Hematopoietic Stem Cell Transplant: Mixed Donor-Recipient Primitive Mesenchymal Proliferation of the Liver. Pediatric and Developmental Pathology, 2021, 24, 366-370.	0.5	0
98	Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 5074-5074.	0.6	0
99	Eosinophilia, Positive ANA, and Hypergammaglobulinemia at Presentation of Extensive Chronic GVHD in Children: A Childrenâ€™s Oncology Group Study.. Blood, 2005, 106, 5375-5375.	0.6	0
100	Fewer Relapses Following Unrelated Donor Cord Blood (UDCB) Compared to Related or Unrelated Bone Marrow (BM) or Peripheral Blood Cell (PBSC) Transplant in the Treatment of Childhood Relapsed and Very High Risk Acute Lymphoblastic Leukemia (ALL).. Blood, 2006, 108, 3153-3153.	0.6	0
101	Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL.. Blood, 2006, 108, 2876-2876.	0.6	0
102	Modest Prolongation of Survival for Patients 60-80 Year at Time of Acute Myelogenous Leukemia (AML) Diagnosis Who Are Treated with Conventional AML Therapy: A Provincial Cohort Analysis.. Blood, 2009, 114, 4125-4125.	0.6	0
103	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.	0.6	0
104	Recovery Of Myeloid Derived Suppressor Cell Subsets Following Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation. Blood, 2013, 122, 4617-4617.	0.6	0
105	Intergraft Variability in Nonhematopoietic Immunoregulatory Cell Number and Expression of Immune Checkpoint Inhibitor Receptors and Ligands in Both Allo- and Autografts: Potential Target for Intervention. Blood, 2016, 128, 3382-3382.	0.6	0
106	Provincial Disparities in Access to Allogeneic Transplant in Canada. Blood, 2018, 132, 4742-4742.	0.6	0